Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May 18;23(4):177-181.
doi: 10.1080/10937404.2020.1752340. Epub 2020 Apr 12.

Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review

Affiliations
Review

Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review

Boscolli Barbosa Pereira. J Toxicol Environ Health B Crit Rev. .

Abstract

As a result of the 2019 coronavirus disease pandemic (COVID-19), there has been an urgent worldwide demand for treatments. Due to factors such as history of prescription for other infectious diseases, availability, and relatively low cost, the use of chloroquine (CQ) and hydroxychloroquine (HCQ) has been tested in vivo and in vitro for the ability to inhibit the causative virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, even though investigators noted the therapeutic potential of these drugs, it is important to consider the toxicological risks and necessary care for rational use of CQ and HCQ. This study provides information on the main toxicological and epidemiological aspects to be considered for prophylaxis or treatment of COVID-19 using CQ but mainly HCQ, which is a less toxic derivative than CQ, and was shown to produce better results in inhibiting proliferation of SARS-CoV-2 based upon preliminary tests.

Keywords: Toxicology; health care; public health; retinopathy; screening.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Toxicological and epidemiological aspects to be considered for prophylaxis or treatment of COVID-19 using CQ and HCQ. (a) Physicochemical properties of chloroquine (CQ) and hydroxychloroquine (HCQ); (b) Incidence of side effects in patients on long-term HCQ therapy; (c) Prescription of CQ | HCQ and patient-care in treatment of COVID-19. Figure 1B. * In all studies the most important predictor of hydroxychloroquine retinal toxicity was the duration of use (cumulative dose).

References

    1. Al-Bari M., and Alim A.. 2017. Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases. Pharmacol. Res. Pers. 5:1–13. doi:10.1002/prp2.293. - DOI - PMC - PubMed
    1. Cabral R. T. S., Klumb E. M., Couto M. I. N. N., and Carneiro S.. 2019. Evaluation of toxic retinopathy caused by antimalarial medications with spectral domain optical coherence tomography. Arq. Bras. Oftalmol. 82:12–17. doi:10.5935/0004-2749.20190002. - DOI - PubMed
    1. Castrejón I., Tani C., Jolly M., Huang A., and Mosca M.. 2014. Indices to assess patients with systemic lupus erythematosus in clinical trials, long-term observational studies, and clinical care. Clin. Exp. Rheumatol. 32 (5 Suppl 85):S85–S95. - PubMed
    1. Chatre C., Roubille F., Vernhet H., Jorgensen C., and Pers Y. M.. 2018. Cardiac complications attributed to chloroquine and hydroxychloroquine: A systematic review of the literature. Drug Saf. 41:919–31. doi:10.1007/s40264-018-0689-4. - DOI - PubMed
    1. Gossec L., Molto A., Romand X., Puyraimond-Zemmour D., Lavielle M., Beauvais C., Senbel E., Flipo R. M., Pouplin S., Richez C., et al. 2019. Recommendations for the assessment and optimization of adherence to disease-modifying drugs in chronic inflammatory rheumatic diseases: A process based on literature reviews and expert consensus. Joint Bone Spine 86:13–19. doi:10.1016/j.jbspin.2018.08.006. - DOI - PubMed

Publication types

MeSH terms